Mayo Clinic Ventures

Submit a New Inquiry

Technology #2015-312 - Methods of Treating Cancer with PK1 or Aurora Kinase Inhibitors by Using Parkin as a Biomarker

Mayo Clinic Ventures contracts with Nouvant to provide this service.

Your inquiry will be sent to this technology's managers. All fields are required unless otherwise noted.



By submitting this inquiry you accept the terms of the Privacy Policy and Terms of Service.

Powered by Nouvant